The CBD market surge in the last few years has been well documented and all reports seem to project continued growth of revenues over the coming years. CNN said, “These hemp farmers are getting rich with CBD.” For farmers, growing hemp is a booming business. And it’s much more profitable than growing corn or soybeans. In the U.S., sales could surge… from $591 million last year . . . to $22 billion within just three years.” An article from Wyatt Research added: “Today, CBD is getting most of the attention. For growers, the next generation of hemp will be even more profitable. It’s called CBG. It’s the precursor cannabinoid to both CBD and THC. And it’s currently being researched for a wide range of uses including psoriasis, eczema and as a cosmetic additive. CBG is essentially the next type of cannabinoid that will be researched, developed and put into thousands of mainstream products. The article continued projecting that hemp growers will be getting into CBG: “Today, production of CBG is very low. And that means prices for CBG are five times higher than CBD! Consider these numbers: One acre of farmland planted for CBD will generate $61,380 in revenue. Yet that same acre planted with hemp for CBG will earn $306,900!”. Active cannabis companies in the markets this week include: SponsorsOne Inc. (OTCPK: SPONF) (CSE: SPO), The Supreme Cannabis Company, Inc. (OTCQX: SPRWF) (TSX: FIRE), Cresco Labs Inc. (OTCQB: CRLBF) (CSE: CL), Aurora Cannabis Inc. (NYSE: ACB) (TSX: ACB), Aphria Inc. (NYSE: APHA) (TSX: APHA).
An article in The Green Fund echoed those reports saying: “CBD or Cannabidiol, has taken the world by storm over the last few years, thanks to the introduction of the US Farm Bill in 2018. CBD has appeared in every product from coffee to cocktails, to even pet treats and beauty products. However, CBD isn’t the only cannabinoid in town… it’s time to learn about CBG.” The Green Fund commentary continued: “Although CBG is just hitting the markets, it was actually first discovered by researchers in the 1960’s. CBG is the main element that the other cannabinoids are created from, hence being commonly referred to as the “stem cell.”
SponsorsOne Inc. (OTCPK: SPONF) (CSE: SPO) BREAKING NEWS: SponsorsOne Introduces Oral Dissolving CBG Tablet – Company Adds Another CBG Product To Its GO Nutraceutical Branded Line Of “Cannabis 2.0” Products – SponsorsOne, a company that utilizes its proprietary platform that combines digital marketing, wholesale and retail distribution, branding and operational & funding capital, giving it a competitive first mover advantage in rapidly building, launching and selling proprietary brands focused in the craft Alcohol, Functional Beverage and Cannabis Sectors, today announced that It has introduced another innovative CBG product, under the marketing management agreement with GO Nutraceutical’s branded line of “Cannabis 2.0” products.
The company, which recently launched a line of flavored, chewable tablets delivering a 20mg dose of CBG, has now added a CBG sublingual dissolving tablet that delivers 10mg in a very small 6mm size also produced by GO Nutraceuticals. Sublingual dissolving tablets are placed under the tongue triggering much higher bioavailability which results in faster absorption into the body.
As with the chewable product, this will be sold direct to consumer through GO Nutraceuticals’ online store and through SPO’s wholesale and retail distribution channel and the company’s rapidly expanding influencer network.
Myles Bartholomew, CEO of SponsorsOne, said: “Oral dissolving CBG tablets are one of the more unique offerings in our solid oral dose line. At 10mg and only 6mm round, the tiny size tablet melts perfectly in the mouth without the need for digestion. Oral dissolving tablets are new to the cannabis industry, but they are showing great potential. The product is easy and enjoyable to consume, the deliveries are small, and it tastes great. But it is not only our delivery system that is the key here, it is fact that we are utilizing CBG, which as we have said before, has been shown to possess enormous therapeutic promise, and has been called the holy grail of cannabinoids. We have taken the knowledge of the pharmaceutical industry and applied it to natural extracts to create the next innovative wave of cannabis deliveries. We believe this will help us separate the company from others in the market and will increase revenues and bring value to our shareholders.” Read this and more news for SponsorsOne at: https://www.financialnewsmedia.com/news-spo/